NEUVIS - Trademark Details
Status: 641 - Non-Final Action - Mailed
Serial Number
79268366
Word Mark
NEUVIS
Status
641 - Non-Final Action - Mailed
Status Date
2022-01-21
Filing Date
2019-07-31
Mark Drawing
4000 - Standard character mark
Typeset
Attorney Name
Law Office Assigned Location Code
O20
Employee Name
DANTZLER, LAUREN ALEXA
Statements
Goods and Services
Pharmaceutical preparations, namely, pharmaceutical preparations for prevention, management or treatment of inflammatory disorders, neurological disorders, psychiatric disorders, malignancy, immune disorders, metabolic disorders, infectious diseases, gastrointestinal disorders, cardiovascular disorders, cancer, pain; Pharmaceutical preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavior modification, schizophrenia, bi-polar disorder, pain; Veterinary preparations derived from natural sources namely, plants, herbs, and flowers for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Plant extracts for medical, pharmaceutical and veterinary use; Biochemical and biological products, in the nature of terpenophenolics, terpenoids and flavones for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Biochemical and biological products, namely, terpenophenolics, terpenoids and flavones for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical preparations for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical preparations for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for medical and pharmaceutical use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, endometriosis, dementia, Alzheimer's disease, Parkinson's disease, gastrointestinal disorder, inflammatory bowel disease, Crohn's, ulcerative colitis, glaucoma, hypertension, anxiety, depression, stress, mood disorder, substance abuse, addiction, insomnia, sleep disorder, fatigue, eating disorder, appetite modification, muscle spasms, multiple sclerosis, muscle tension, tension, behavioural modification, schizophrenia, bi-polar, pain; Chemical products, namely, aminoalkylindoles, 1,5-diarylpyrazoles, quinolines, arylsulfonamides, eicosanoids for veterinary use for the treatment of seizures, nausea, vomiting, inflammation, arthritis, autoimmune disorders, cancer, diabetes, glaucoma, anxiety, appetite modification, muscle spasms, behavioural modification, pain; Analgesic preparations; Anti-inflammatory preparations; Anti-microbial preparations for inhibiting microbiological growth and infection in medical and veterinary situations; Anti-nauseants treatment preparations; Anti-spasmodics; Anticonvulsants; Appetite stimulant preparations for medical purposes; Nausea medications, namely, nausea treatment preparations
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
005, 006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-10-04
Primary Code
005
Current Trademark Owners
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
99 - Other (limited company (ltd.)).
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Charles G. Zug
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1489529
International Registration Date
2019-07-31
International Publication Date
2019-09-26
International Renewal Date
2029-07-31
Auto Protection Date
2021-03-26
International Status
001 - Request for extension of protection established
International Status Date
2019-09-26
Priority Claimed In
True
Priority Claimed Date
2019-03-11
First Refusal In
True
Trademark Events
Event Date | Event Description |
2019-09-26 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
2019-10-04 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2019-10-08 | APPLICATION FILING RECEIPT MAILED |
2019-10-25 | ASSIGNED TO EXAMINER |
2019-11-05 | ASSIGNED TO EXAMINER |
2020-07-17 | ASSIGNED TO EXAMINER |
2020-07-24 | NON-FINAL ACTION WRITTEN |
2020-07-25 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
2020-08-28 | REFUSAL PROCESSED BY MPU |
2020-09-09 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
2020-09-26 | REFUSAL PROCESSED BY IB |
2021-03-03 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
2021-03-03 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
2021-03-09 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-03-09 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-03-09 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-03-20 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
2021-04-14 | NON-FINAL ACTION WRITTEN |
2021-04-14 | NON-FINAL ACTION E-MAILED |
2021-04-14 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2021-10-14 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-10-14 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-10-15 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2022-01-21 | NON-FINAL ACTION WRITTEN |
2022-01-21 | NON-FINAL ACTION E-MAILED |
2022-01-21 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |